When did NovoCure report Q3 2024 earnings?

NovoCure (NVCR) reported Q3 2024 earnings on October 30, 2024 before market open.

What were NovoCure's Q3 2024 revenue and EPS?

NovoCure reported revenue of $155.1M and eps of $-0.28 for Q3 2024.

Did NovoCure beat estimates in Q3 2024?

Revenue beat the consensus estimate of $153.0M by $2.0M. EPS beat the consensus estimate of $-0.34 by $0.06.

Where can I find NovoCure's Q3 2024 SEC filings?

You can read the 10-Q periodic report (0001645113-24-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.

NovoCure NVCR Q3 2024 earnings

Reported October 30, 2024 · Before market open

Revenue$155.1MBeat by $2.0M

EPS-$0.28Beat by $0.06

Revenue estimate$153.0M

EPS estimate-$0.34

Next report

Date not yet announced

Financials

Q3 2024

Income statement

See full

Revenue$155.1M+21.8%

Gross profit$119.7M+25.7%

Operating income-$32.1M+44.9%

Net income-$30.6M+38.2%

EPS (diluted)-$0.28+39.1%

Balance sheet

See full

Cash & equivalents$185.4M+19.7%

Total debt$21.1M-96.4%

Total equity$360.8M-8.4%

Total assets$1.2B+6.6%

Cash flow

See full

Operating cash flow$10.4M+154%

CapEx$10.7M+47.3%

Free cash flow-$307.0K+98.8%

Valuation & ratios

Valuation

as of 09/30/24

See full

Market cap$1.68B-2.4%

Enterprise value$1.52B-29.7%

P/S2.9×-0.5×

Profitability

See full

Gross margin76.4%+1.1pp

Operating margin-27.5%-7.6pp

Net margin-25.9%-6.5pp

FCF margin-13.5%—

Returns & leverage

See full

Return on equity-39.7%-5.3pp

Debt / equity0.1×-1.4×

Current ratio1.5×-5.2×

Segments

By geography

See full

United States$98.3M—

Germany$17.0M—

France$15.2M—

Japan$8.6M—

Greater China$4.6M—

Versus estimates

Revenue

Q2 2026$183.6MBeat by $11.1M Q1 2026$174.1MBeat by $6.3M Q4 2025$174.4MIn line Q3 2025$167.2MMiss by $7.2M Q2 2025$158.8MIn line Q1 2025$155.0MBeat by $1.1M

Diluted EPS

Q2 2026-$0.13Beat by $0.20 Q1 2026-$0.62Miss by $0.11 Q4 2025-$0.22Beat by $0.19 Q3 2025-$0.33Beat by $0.09 Q2 2025-$0.36Beat by $0.03 Q1 2025-$0.31Beat by $0.16

Ask the moment NovoCure reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did NovoCure report Q3 2024 earnings?: NovoCure (NVCR) reported Q3 2024 earnings on October 30, 2024 before market open.
What were NovoCure's Q3 2024 revenue and EPS?: NovoCure reported revenue of $155.1M and eps of $-0.28 for Q3 2024.
Did NovoCure beat estimates in Q3 2024?: Revenue beat the consensus estimate of $153.0M by $2.0M. EPS beat the consensus estimate of $-0.34 by $0.06.
Where can I find NovoCure's Q3 2024 SEC filings?: You can read the 10-Q periodic report (0001645113-24-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.